-
Your selected country is
Australia
- Change country/language
Old Browser
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
Western blot analysis of GGA3 on a Jurkat cell lysate (Human T-cell leukemia; ATCC TIB-152). Lane 1: 1:2500, lane 2: 1:5000, lane 3: 1:10,000 dilution of the mouse anti-human GGA3 antibody.
Immunofluorescence staining of human endothelial cells.
BD Transduction Laboratories™ Purified Mouse Anti-Human GGA3
BD Transduction Laboratories™ Purified Mouse Anti-Human GGA3
Regulatory Status Legend
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Preparation And Storage
Recommended Assay Procedures
Western blot: Please refer to http://www.bdbiosciences.com/pharmingen/protocols/Western_Blotting.shtml
Product Notices
- Since applications vary, each investigator should titrate the reagent to obtain optimal results.
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- Source of all serum proteins is from USDA inspected abattoirs located in the United States.
Companion Products
The ADP-ribosylation factors (ARFs) are a family of small GTPases in the ARF superfamily that include ARFs and ARF-like (ARLs) proteins. At least six ARFs have been identified in humans: ARF1, ARF2, ARF3, ARF4, ARF5, and ARF6. ARFs are involved in intravesicular acidification and fusion of microsomal vesicles, endosome fusion, nuclear membrane assembly, and formation of clathrin-coated vesicles. GGAs are ARF-binding proteins that act as adaptor coat proteins associated with the Golgi complex. GGA1, GGA2, and GGA3 are homologous proteins that contain N-terminal VHS domains, a GGA and TOM homology region (GAT), and a C-terminal region homologous to the ear domain of γ-adaptins. GGAs co-localize with Golgi markers in the TGN, and GGA3 is found present in coated vesicles and buds associated with the TGN. The GAT domain of GGA3 facilitates ARF1 binding, Golgi localization, and dissociation from ARF-regulated membranes. The C-terminal region of GGAs bind to MAP1A and rabaptin-5, which are binding partners of γ-adaptins. Overexpression of GGAs alters the distribution of markers normally found in the TGN. Thus, GGAs are ARF binding proteins that regulate vesicle dynamics in the TGN.
Development References (3)
-
Boman AL, Zhang C, Zhu X, Kahn RA. A family of ADP-ribosylation factor effectors that can alter membrane transport through the trans-Golgi. Mol Biol Cell. 2000; 11(4):1241-1255. (Biology). View Reference
-
Dell'Angelica EC, Puertollano R, Mullins C, et al. GGAs: a family of ADP ribosylation factor-binding proteins related to adaptors and associated with the Golgi complex. J Cell Biol. 2000; 149(1):81-94. (Biology). View Reference
-
Hirst J, Lui WW, Bright NA, Totty N, Seaman MN, Robinson MS. A family of proteins with gamma-adaptin and VHS domains that facilitate trafficking between the trans-Golgi network and the vacuole/lysosome. J Cell Biol. 2000; 149(1):67-80. (Biology). View Reference
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.
Refer to manufacturer's instructions for use and related User Manuals and Technical Data Sheets before using this product as described.
Comparisons, where applicable, are made against older BD technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.